Guidance for assessment and evaluation of changes to drug delivery systems
This document provides guidance for assessment and evaluation of planned changes to drug delivery systems that are integral with, packaged with, or cross-labelled for use with a specified medicinal product.
This document is applicable to the drug delivery system's lifecycle from registration clinical studies to end-of-life.
This document is applicable to the assessment of changes within the following drug delivery systems:
NOTE: These are covered by the ISO 11608 series, ISO 20072 and ISO 21649, respectively.
This document might also be useful for assessing and evaluating changes to other drug delivery devices or systems.
Examples of changes that are within the scope of this document include but are not limited to the following:
Revisions or additions of software are within the scope of this document. The software can either be integrated into the physical drug delivery system, separate, or both.
The applicability of this document to non-integrated software is relevant to the extent that those software changes can impact the drug delivery system and/or impact how users interact with it.
Depending on the nature of the change, there can be additional assessments and resulting activities, which can be outside the scope of this document.
This document does not provide guidance for defining the objective of the change, nor the various potential opportunities/options for fulfilling this objective.
Failed to load document history.
| Publish Date | Document Id | Type | View |
|---|